683 results match your criteria lt4

Oral Levothyroxine Treatment in Lithium Intoxication- Induced Myxedema Coma: A Case Report.

Po-Hsuan Kao

J Acute Med 2021 Jun;11(2):68-71

National Taiwan University Hospital Department of Emergency Medicine Taipei Taiwan.

Lithium intoxication-induced myxedema coma, a rare but dangerous condition of severe hypothyroidism, can be easily misdiagnosed in patients without history of hypothyroidism. The objective of this case report is to describe a lithium-treated patient who presented to emergency department with obtundation and moderate hypothermia and was diagnosed with myxedema coma and lithium toxicity. A 64-year-old female presented to the emergency department with obtundation and hypothermia. Read More

View Article and Full-Text PDF

Efficiency enhancement of a new cellulase cocktail at low enzyme loading for high solid digestion of alkali catalyzed atmospheric glycerol organosolvent pre-treated sugarcane bagasse.

Bioresour Technol 2021 Jul 10;338:125505. Epub 2021 Jul 10.

School of Life Sciences, University of Science and Technology of China, Hefei, China.

The acquisition during biomass saccharification of elevated levels of fermentable sugars with lower cellulase concentration is central to ensuring an economically viable and industrially relevant hydrolytic process. Thus, using a new cellulase preparation (LT4) at low cellulase loading (2 mg protein/g dried substrate), this study assessed the possible boosting effect of integrating accessory enzymes and additives on high-solids hydrolysis of sugarcane bagasse via fed-batch feeding. Hydrolysis which commenced with initial 8% solids loading and subsequent substrate feeding of 4% solids at 6 h, 18 h, and 24 h respectively, proved optimal for the 20% high-solids saccharification producing 158 g/L total sugars and 83% glucose yield after 72 h with the combined optimized additives and accessory enzymes. Read More

View Article and Full-Text PDF

Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+Liothyronine in hypothyroidism.

J Clin Endocrinol Metab 2021 Jun 29. Epub 2021 Jun 29.

Walter Reed National Military Medical Center, Bethesda MD.

Introduction: Studies comparing LT4 therapy with LT4+LT3 or desiccated thyroid extract (DTE) did not detect consistent superiority of either treatment. Here we investigated these therapies, focusing on the whole group of LT4-treated hypothyroid patients, while also exploring the most symptomatic patients.

Methodology: Prospective, randomized, double-blind, crossover study of 75 hypothyroid patients randomly allocated to one of three treatment arms, LT4, LT4+LT3 and DTE, for 22 weeks. Read More

View Article and Full-Text PDF

High Prevalence of Hearing Impairment in Primary Congenital Hypothyroidism.

Eur Thyroid J 2021 Jun 3;10(3):215-221. Epub 2020 Sep 3.

Pediatric Endocrine Institute, Ha'Emek Medical Center, Afula, Israel.

Background: An association between hearing impairment (HI) and congenital hypothyroidism (CH) has been reported previously. However, in general, studies were retrospective and had small sample sizes, and the results were variable and inconclusive. The aim of our study was to assess the prevalence of HI among patients with CH and to examine factors potentially predictive of HI including severity of CH, etiology of CH, and timing of treatment initiation. Read More

View Article and Full-Text PDF

Calculation of left ventricular volumes and systolic indices in monitoring the therapeutic effect of levothyroxine replacement therapy in subclinical hypothyroidism.

Int J Clin Pract 2021 Jun 26:e14577. Epub 2021 Jun 26.

Institute for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, University of Belgrade School of Medicine, Belgrade, Serbia.

Background/aim: Subclinical hypothyroidism (SCH) is defined as high thyroid-stimulating hormone (TSH) and normal thyroxine (T4) levels. Data on the effects of early substitution with levothyroxine on psychophysical health in SCH are not consistent enough to support its general administration. The aim of this study was to examine the effect of 3-months levothyroxine (LT4) treatment on cardiovascular function in symptomatic SCH with TSH <10 mIU/L. Read More

View Article and Full-Text PDF

Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population.

Eur Arch Otorhinolaryngol 2021 Jun 24. Epub 2021 Jun 24.

Oncology Apollo Group of Hospitals, Plot #13, Parsik Hill Road, Off Uran Road, Sector - 23, CBD Belapur, Opp. Nerul Wonders Park, Navi Mumbai, Maharashtra, India.

Background: Thyroid withdrawal in preparation for radioiodine ablation (RIA) may have a profound impact on health-related quality of life (HRQL). Cost implications and scheduling limit the use of recombinant TSH and triiodothyronine (T3) with its shorter half-life is a conceptually attractive alternative.

Methods: Prospective cohort study design with patients having withdrawal of thyroxine (n = 37) or T3 supplementation (n = 33). Read More

View Article and Full-Text PDF

Auto-destruction of the thyroid gland and coexisting glutamic acid decarboxylase mediated neurological disease in an adolescent: an unusual presentation of autoimmunity.

J Pediatr Endocrinol Metab 2021 Jun 24. Epub 2021 Jun 24.

Pediatric Endocrinology, NYU Langone Medical Center, New York, USA.

Objectives: Hashimoto's thyroiditis (HT) is characterized by lymphocytic thyroid infiltration. Gradual thyroid failure can occur due to thyroid cell apoptosis. Rarely neurological autoimmunity due to glutamic acid decarboxylase (GAD) antigen can co exist with HT. Read More

View Article and Full-Text PDF

Use of Statins Among Patients Taking Levothyroxine: an Observational Drug Utilization Study Across Sites.

J Endocr Soc 2021 Jul 6;5(7):bvab038. Epub 2021 Mar 6.

Section of Adult and Pediatric Endocrinology and Metabolism, University of Chicago, Chicago, IL 60637, USA.

Context: Treatment with levothyroxine (LT4) that normalize serum thyrotropin (TSH) is expected to restore lipid metabolism.

Objective: To assess statin utilization in LT4-treated patients through an observational drug utilization study.

Methods: Three sites were involved: (1) 10 723 outpatients placed on LT4 during 2006-2019 identified from the Clinical Research Data Warehouse of the University of Chicago; (2) ~1. Read More

View Article and Full-Text PDF

Subclinical Hypothyroidism: Prevalence, Health Impact, and Treatment Landscape.

Endocrinol Metab (Seoul) 2021 Jun 18;36(3):500-513. Epub 2021 Jun 18.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.

Subclinical hypothyroidism (sHypo) is defined as normal serum free thyroid hormone levels coexisting with elevated serum thyroid-stimulating hormone (TSH) levels. sHypo is a common condition observed in clinical practice with several unique features. Its diagnosis should be based on an understanding of geographic and demographic differences in biochemical criteria versus a global reference range for TSH that is based on the 95% confidence interval of a healthy population. Read More

View Article and Full-Text PDF

Role of thyroid hormone therapy in depressive disorders.

M Bauer P C Whybrow

J Endocrinol Invest 2021 Jun 15. Epub 2021 Jun 15.

Department of Psychiatry and Biobehavioral Sciences, The Semel Institute for Neuroscience and Human Behavior University of California Los Angeles (UCLA), Los Angeles, CA, USA.

Purpose: The close association among thyroid metabolism, mood disorders and behavior has long been known. The old and modern uses of thyroid hormones to modulate the expression of depression and bipolar disorder and to improve clinical outcome when used in conjunction with psychotropic medications.

Methods: A literature search was performed to identify studies investigating the effects of thyroid hormone treatment in patient s with mood disorders. Read More

View Article and Full-Text PDF

Decreased Expression of Ileal Thyroid Hormone Transporters in a Hypothyroid Patient: A Case Report.

Front Endocrinol (Lausanne) 2021 26;12:664839. Epub 2021 May 26.

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Background: Malabsorption of levothyroxine (LT4) is a common problem faced in clinical practice. It is usually solved, if there are no complexities including gastrointestinal absorption disorder, by taking medicines on an empty stomach and avoiding foods interfering with LT4. Herein we present a rare case of a patient exhibiting malabsorption of LT4 with decreased membranous expression of ileal transporters. Read More

View Article and Full-Text PDF

Rhabdomyolysis-induced acute kidney injury in a patient with non-compliance to levothyroxine therapy.

Endocrinol Diabetes Metab Case Rep 2021 Jun 1;2021. Epub 2021 Jun 1.

Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Pikeville Medical Center, Pikeville, Kentucky, USA.

Summary: Hypothyroidism is a common medical condition and is often easily managed with excellent outcomes, when treated adequately. Compliance with levothyroxine (LT4) therapy is often compromised because of the need for a daily and lasting schedule. Overt rhabdomyolysis due to under-treatment or non-compliance is a rare occurrence. Read More

View Article and Full-Text PDF

Modeling of levothyroxine in newborns and infants with congenital hypothyroidism: challenges and opportunities of a rare disease multi-center study.

J Pharmacokinet Pharmacodyn 2021 Jun 11. Epub 2021 Jun 11.

Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel UKBB, University of Basel, Basel, Switzerland.

Modeling of retrospectively collected multi-center data of a rare disease in pediatrics is challenging because laboratory data can stem from several decades measured with different assays. Here we present a retrospective pharmacometrics (PMX) based data analysis of the rare disease congenital hypothyroidism (CH) in newborns and infants. Our overall aim is to develop a model that can be applied to optimize dosing in this pediatric patient population since suboptimal treatment of CH during the first 2 years of life is associated with a reduced intelligence quotient between 10 and 14 years. Read More

View Article and Full-Text PDF

Inhibitors of A Disintegrin And Metalloproteinases-10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.

Haematologica 2021 Jun 10. Epub 2021 Jun 10.

Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute.

Shedding of A Disintegrin And Metalloproteinases (ADAM10) substrates, like TNFα or CD30, can affect both anti-tumor immune response and antibody-drug-conjugate (ADC)-based immunotherapy. We have published two new ADAM10 inhibitors, LT4 and MN8 able to prevent such shedding in Hodgkin lymphoma (HL). Since tumor tissue architecture deeply influence the outcome of anti-cancer treatments, we set up new three-dimensional (3D) culture systemsto verify whether ADAM10 inhibitors can contribute to, or enhance, the anti-lymphoma effects of the ADC brentuximab-vedotin (BtxVed). Read More

View Article and Full-Text PDF

Increased Thyroid-Hormone Requirements Consistent With Type 3 Deiodinase Induction Related to Ibrutinib in a Thyroidectomized Woman.

AACE Clin Case Rep 2021 Mar-Apr;7(2):121-123. Epub 2020 Dec 28.

Division of Endocrinology, Diabetes and Bone Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.

Objective: Tyrosine-kinase inhibitors (TKIs) are chemotherapeutic agents associated with increased thyroid-hormone requirements and altered deiodinase activity. We present the first case to link these findings to the TKI ibrutinib.

Methods: Serial thyroid-stimulating hormone (TSH), free-thyroxine (FT4), free-triiodothyronine (FT3), and reverse-triiodothyronine (rT3) levels were assessed. Read More

View Article and Full-Text PDF
December 2020

Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: A Thesis* Questionnaire Survey of Romanian Physicians *Thesis: Treatment of Hypothyroidism in Europe by Specialists: an International Survey.

Acta Endocrinol (Buchar) 2020 Oct-Dec;16(4):462-469

"Carol Davila" University of Medicine and Pharmacy - Endocrinology, Bucharest, Romania.

Objective: Romania has no national guidelines for hypothyroidism treatment, nor are there any recommendations from national societies to adhere to international guidelines. Our aim was to identify the attitudes of Romanian physicians relating to hypothyroidism treatment focusing on available formulations of levothyroxine (LT4).

Methods: All 748 members of the Romanian Society of Endocrinology were invited to participate in a web-based survey. Read More

View Article and Full-Text PDF

The positive effect of black seed (Nigella sativa L.) essential oil on thyroid hormones in rats with hypothyroidism and hyperthyroidism.

J Food Biochem 2021 Jun 3:e13801. Epub 2021 Jun 3.

Department of Physiology, Faculty of Milas Veterinary Medicine, University of Mugla Sıtkı Kocman, Mugla, Turkey.

In our study, the effect of essential oil obtained from Nigella sativa L. (NSE) on thyroid hormones and antioxidant balance in hypothyroidism (HT) and hyperthyroidism (HP) models induced by propylthiouracil(PTU) and L-thyroxine(LT ), respectively, in rats were investigated for 4 weeks. NSE was administered by gastric gavage at a dose of 200 mg/kg body weight. Read More

View Article and Full-Text PDF

Re-Evaluation of the Prevalence of Permanent Congenital Hypothyroidism in Niigata, Japan: A Retrospective Study.

Int J Neonatal Screen 2021 May 28;7(2). Epub 2021 May 28.

Department of Pediatrics, Nagaoka Institute for Severely Handicapped Children, Nagaoka 940-2135, Japan.

Although newborn screening (NBS) for congenital hypothyroidism (CH) in Japan started more than 40 years ago, the prevalence of CH remains unclear. Prevalence estimations among NBS-positive CH individuals include those with transient hypothyroidism and transient hyperthyrotropinemia, and re-evaluation with increasing age is necessary to clarify the actual incidence. Thus, we re-evaluated the incidence of permanent CH. Read More

View Article and Full-Text PDF

Positive Impact of Levothyroxine Treatment on Pregnancy Outcome in Euthyroid Women with Thyroid Autoimmunity Affected by Recurrent Miscarriage.

J Clin Med 2021 May 13;10(10). Epub 2021 May 13.

Physiopathology of Reproduction and Andrology Unit, Department of Gender, Parenting, Child and Adolescent Medicine, Sandro Pertini Hospital, Via dei Monti Tiburtini 385/389, 00157 Rome, Italy.

Impaired thyroid hormone availability during early pregnancy is associated with recurrent miscarriage (RM) and adverse pregnancy outcomes. The main cause of thyroid dysfunction is thyroid-related autoimmunity (TAI), characterized by a significantly higher serum level of thyroid-stimulating hormone (TSH) compared to that of women without thyroid autoimmunity. TAI is associated with a significantly increased risk of miscarriage, and the incidence of TAI in women experiencing RM is higher compared to normal fertile women. Read More

View Article and Full-Text PDF

Use of thyroid hormones in hypothyroid and euthyroid patients: a THESIS* questionnaire survey of Polish physicians *THESIS: Treatment of Hypothyroidism in Europe by Specialists: an International Survey.

Endokrynol Pol 2021 May 19. Epub 2021 May 19.

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.

Introduction: Over the past several years new evidence on management of hypothyroidism has emerged and has influenced recommendations from professional bodies. The presentation of hypothyroid patients has also changed and increasingly new cases are diagnosed by indiscriminate screening often identifying cases with minor biochemical disturbances. Little is known about the physician responses and attitudes to this changing landscape. Read More

View Article and Full-Text PDF

Evaluation of adherence to levothyroxine and out-of-range thyroid-stimulating hormone levels in pregnant women with primary hypothyroidism.

Int J Clin Pract 2021 Aug 17;75(8):e14312. Epub 2021 May 17.

Internal Medicine Clinics, Kocaeli Derince Training and Research Hospital, University of Health Sciences, Kocaeli, Turkey.

Purpose: Adherence to levothyroxine (LT4) and attaining thyroid-stimulating hormone (TSH) goal in pregnancy has not been well-defined yet. We aimed to investigate adherence to LT4, success to reach TSH goal, and association between them in pregnant women with primary hypothyroidism.

Materials And Methods: Eight-item Morisky Medication Adherence Scale (MMAS-8) was applied in third trimester in pregnant women with primary hypothyroidism (Hashimoto's thyroiditis, surgical hypothyroidism or iodine deficiency) whom LT4 was given for at least 3 months. Read More

View Article and Full-Text PDF

Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach after Total Thyroidectomy.

Thyroid 2021 Jun 22. Epub 2021 Jun 22.

Department of Sustainable Energy Technology, SINTEF Industry, Trondheim, Norway.

After seven decades of levothyroxine (LT4) replacement therapy, dosage adjustment still takes several months. We have developed a decision aid tool (DAT) that models LT4 pharmacometrics and enables patient-tailored dosage. The aim of this was to speed up dosage adjustments for patients after total thyroidectomy. Read More

View Article and Full-Text PDF

Anastrozole Improves Final Adult Height in Severe Hypothyroidism With Rapid Pubertal Progression.

J Endocr Soc 2021 May 20;5(5):bvab025. Epub 2021 Feb 20.

Division of Pediatric Endocrinology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, Rhode Island 02903, USA.

Severe prolonged hypothyroidism due to Hashimoto thyroiditis may lead to rapid pubertal progression and compromised adult height after initiation of levothyroxine (LT4) therapy. There are no reports of aromatase inhibitor use to augment height in these patients. We describe a patient with severe hypothyroidism and growth failure who experienced rapid pubertal and bone age maturation on initiation of LT4 therapy. Read More

View Article and Full-Text PDF

Liothyronine and levothyroxine prescribing in England: A comprehensive survey and evaluation.

Int J Clin Pract 2021 Apr 16:e14228. Epub 2021 Apr 16.

The School of Medicine, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK.

Introduction: The approach to thyroid hormone replacement varies across centres, but the extent and determinants of variation is unclear. We evaluated geographical variation in levothyroxine (LT4) and liothyronine (LT3) prescribing across General Practices in England and analysed the relationship of prescribing patterns to clinical and socioeconomic factors.

Methods: Data was downloaded from the NHS monthly General Practice Prescribing Data in England for the period 2011-2020. Read More

View Article and Full-Text PDF

Subcutaneous administration of levothyroxine: a novel approach to refractory hypothyroidism - A review and a case report.

Arch Endocrinol Metab 2021 Apr 12. Epub 2021 Apr 12.

Department of Internal Medicine I, Paracelsus Medical University of Salzburg, Salzburg, Austria.

Treatment-refractory hypothyroidism is a common clinical finding. Substantial causes include poor compliance and intake failure as well as gastrointestinal diseases, such as inflammatory bowel disease and short bowel syndromes. Increasing oral dosage of levothyroxine (LT4) is not always effective. Read More

View Article and Full-Text PDF

What Is the Quality of Life in Patients Treated with Levothyroxine for Hypothyroidism and How Are We Measuring It? A Critical, Narrative Review.

J Clin Med 2021 Mar 30;10(7). Epub 2021 Mar 30.

Service d'Endocrinologie, Maladies Métaboliques et Nutrition, Pôle Cardio-Vasculaire et Métabolique, Hôpital Larrey, CHU de Toulouse, 31059 Toulouse, France.

Thyroid hormone replacement therapy (THRT, generally using oral levothyroxine (LT4)) is a safe, effective means of treating hypothyroidism. However, a proportion of LT4-treated patients with biochemically normal thyroid function tests complain of persistent symptoms that impact their health-related quality of life (QoL). The objectives of this critical, narrative review of the literature were to identify studies of QoL in LT4-treated patients with hypothyroidism, examine the instruments used to measure QoL, determine whether normal QoL is restored by THRT, and identify factors associated with QoL. Read More

View Article and Full-Text PDF

Therapeutic Equivalence of a New Preparation of Liquid Levothyroxine with Tablets in Patients with Overt Primary Hypothyroidism.

Eur Thyroid J 2021 Mar 23;10(1):59-64. Epub 2020 Jun 23.

Division of Endocrinology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.

Background: A new liquid levothyroxine (LT4) dissolved in glycerol and water has recently been developed by a Greek pharmaceutical company (Uni-Pharma, Athens, Greece).

Objectives: To evaluate the therapeutic equivalence of this new liquid LT4 preparation versus the already existing tablet formulation of the same manufacturer, in order to obtain approval by the Greek National Organization for Medicines.

Methods: This was a prospective, randomized, cross-over phase III study. Read More

View Article and Full-Text PDF

Oral Levothyroxine is an Effective Option for Myxedema Coma: A Single-Centre Experience.

Eur Thyroid J 2021 Mar 11;10(1):52-58. Epub 2020 Jun 11.

Department of Endocrinology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Cochin, India.

Introduction: Myxedema coma is an endocrine emergency with a very high mortality rate. As per the American Thyroid Association, initial thyroid hormone replacement for myxedema coma should be intravenous levothyroxine (LT4). However, in India, the availability of intravenous LT4 is limited. Read More

View Article and Full-Text PDF

Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document.

Eur Thyroid J 2021 Mar 16;10(1):10-38. Epub 2021 Feb 16.

Thyroid Research Group, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Background: Fourteen clinical trials have not shown a consistent benefit of combination therapy with levothyroxine (LT4) and liothyronine (LT3). Despite the publication of these trials, combination therapy is widely used and patients reporting benefit continue to generate patient and physician interest in this area. Recent scientific developments may provide insight into this inconsistency and guide future studies. Read More

View Article and Full-Text PDF

Abnormal Brain Glucose Metabolism in Papillary Thyroid Cancer Patients 4 Weeks After Withdrawal of Levothyroxine: A Cross-Sectional Study Using F-FDG PET/CT.

Front Endocrinol (Lausanne) 2021 11;12:595933. Epub 2021 Mar 11.

Department of Nuclear Medicine, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Background: There is no doubt that thyroid dysfunction is associated with psychiatric disorders. A large amount of thyroid carcinoma patients displayed mood disorders after the withdrawal of levothyroxine (LT4). However, it is unclear whether the disorders are related to the transient withdrawal of LT4, and if yes, what the possible underlying mechanism is. Read More

View Article and Full-Text PDF